Accurate and comprehensive evaluation of

O6-methylguanine-DNA methyltransferase promotor methylation by nanopore sequencing

Skarphedinn Halldorsson [](https://orcid.org/0000-0003-4337-9252) \*1, Richard Mark Nagymihaly1, Areeba Patel [](https://orcid.org/0000-0003-0374-4227) 2,3, Petter Brandal4,6, Ioannis Panagopoulos [](https://orcid.org/0000-0003-2159-5341) 4, Henning Leske [](https://orcid.org/0000-0002-3057-8730) 5,7, Marius Lund-Iversen5, Felix Sahm [](https://orcid.org/0000-0001-5441-1962) 2,3, and Einar O. Vik-Mo [](https://orcid.org/0000-0001-8303-4123) †1,8

1Vilhelm Magnus Laboratory, Institute for Surgical Research, Department of Neurosurgery, Oslo University Hospital, Oslo, Norway

2Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany

3CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK, German Cancer Research Center (DKFZ), Heidelberg, Germany

4Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, Oslo University Hospital

5Department of Pathology, Oslo University Hospital, Oslo, Norway. 6Department of Oncology, Oslo University Hospital, Oslo, Norway 7University of Oslo, Oslo, Norway

8Institute for Clinical Medicine, University of Oslo, Oslo, Norway

\*[skarphedinn.halldorsson@rr-research.no](mailto:skarphedinn.halldorsson@rr-research.no)

†[e.o.vik-mo@medisin.uio.no](mailto:e.o.vik-mo@medisin.uio.no)

**Abstract**

### Aims

Methylation status of the O6-methylguanine-DNA methyltransferase (*MGMT*) promoter re- gion is essential in evaluating the prognosis and predicting the drug response in patients with glioblastoma (GBM). In this study we evaluated the utility of using nanopore long-read sequencing as a method for assessing methylation levels throughout the *MGMT* CpG-island, compared its performance to established techniques, and demonstrated its clinical appli- cability.

### Methods

We analyzed a total of 165 samples from CNS tumors, focusing on the *MGMT* CpG-island us- ing nanopore sequencing. Oxford Nanopore Technologies (ONT) MinION and PromethION flow cells were employed for single sample or barcoded assays, guided by a CRISPR/Cas9 protocol, adaptive sampling or as part of a whole genome sequencing assay. Methylation data obtained through nanopore sequencing were compared to results obtained via pyrose- quencing and methylation bead arrays. Hierarchical clustering was applied to nanopore sequencing data for patient stratification.

### Results

Nanopore sequencing displayed a strong correlation (95%) with pyrosequencing results for the four CpGs of *MGMT* analysed by both methods. The *MGMT*-STP27 algorithm’s classifica- tion was effectively reproduced using nanopore data. Unsupervised hierarchical clustering revealed distinct patterns in methylated and unmethylated samples, providing comparable survival prediction capabilities. Nanopore sequencing yielded high-confidence results in a rapid timeframe, typically within hours of sequencing, and extended the analysis to all 98 CpGs of the *MGMT* CpG-island.

### Conclusions

This study presents nanopore sequencing as a valid and efficient method for determining *MGMT* promotor methylation status. It offers a comprehensive view of the *MGMT* promoter methylation landscape, which enables the identification of potentially clinically relevant sub- groups of patients. Further exploration of the clinical implications of patient stratification using nanopore sequencing of *MGMT* is warranted.

**Keywords:** *MGMT* promoter methylation, Nanopore sequencing, CRISPR/Cas9, Glioblas- toma

# Introduction

Glioblastoma (GBM), IDH-wildtype is the most common aggressive primary malignant brain tu- mor in adults [[24](#_bookmark29)] with a median survival of about 15 months [[32](#_bookmark37)]. Standard treatment for GBM involves surgical resection followed by a combination of radiation and chemotherapy. The fre- quently used chemotherapeutic drug temozolomide (TMZ) is an alkylating agent that induces methylation of O-6 guanidine residues in dividing cells, leading to DNA damage and apoptosis [[39](#_bookmark44)]. Although often well tolerated, TMZ can cause a range of side effects. TMZ is therefore suggested to be limited to patients that are likely to benefit from it and withheld from patients that most likely will experience side effects without improvement in survival [[14](#_bookmark19)]. The alkylating effects of TMZ are countered by the DNA repair protein O-6-methylguanine-DNA methyltrans- ferase (MGMT). Methylation of the *MGMT* promoter is believed to silence its expression, thereby increasing sensitivity of GBM tumor cells to TMZ [[22](#_bookmark27)]. The presence of *MGMT* promoter methy- lation has been associated with increased survival in GBM patients treated with temozolomide and radiation therapy [[13](#_bookmark18)]. *MGMT* promoter methylation status is therefore an important factor for the management and treatment of GBM [[6](#_bookmark11)].

Various methods are utilized to directly measure or estimate *MGMT* promoter methylation, in- cluding methylation-specific PCR, pyrosequencing, Sanger sequencing or methylation bead ar- ray [[17](#_bookmark22), [30](#_bookmark35)]. All these methods rely on bisulfite conversion of native DNA and PCR amplification prior to analysis and only include a subset of the 98 CpG sites in the CpG-island of *MGMT*

[[21](#_bookmark26)] ([Figure 1a](#_bookmark1)). For example, the Qiagen *MGMT* pyrosequencing kit, which is widely used in the clinical setting, detects methylation on 4 CpG sites (76-79) in the *MGMT* CpG-island. In addition, there is neither a clear consensus of the best cut-off values for the classification of clinically relevant methylated or unmethylated samples, nor on the optimal method to use [[3](#_bookmark7)]. In recent years, advances in sequencing technology have enabled more sensitive and accurate detection of DNA methylation. Nanopore sequencing, which uses a nanopore-based sensor to detect changes in electrical current as nucleic acids (DNA or RNA) pass through a pore, can detect epigenetic modifications, such as methylation, directly from the raw current signal [[16](#_bookmark21)]. Due to the long-read nature of nanopore sequencing, it also affords methylation analysis of far longer sequences than methylation specific PCR, pyrosequencing or methylation bead array. Consequently, nanopore sequencing offers an overview of the methylation status of all CpGs of the *MGMT* CpG-island, using native genomic DNA without bisulfite conversion, which can be

both time and cost efficient in a clinical setting [[19](#_bookmark24)]. Recently developed enrichment methods such as nanopore Cas9 targeted sequencing (nCATs) [[8](#_bookmark13)] and adaptive sampling (AS) [[26](#_bookmark31)] can be used to direct the sequencing effort to specific genomic regions. In this study, we com- pared the results of nanopore sequencing of the *MGMT* promoter region of 165 samples from central nervous system (CNS) tumors, including 103 GBMs, with results obtained from standard diagnostic methods such as pyrosequencing or Illumina 850K bead array.

# Materials and Methods

## Patients and samples

Samples from four independent cohorts were included into this study; 1) Retrospective anal- ysis of DNA from 64 CNS tumor samples provided by the Institute for Cancer Genetics and Informatics, Oslo University Hospital that were screened for *MGMT* promoter methylation us- ing the Qiagen® *MGMT* pyrosequencing kit (MGMT pyro kit). These samples are referred to as ”Retrospective nCATs”. 2) Retrospective analysis of 67 sequences generated as part of the Rapid-CNS adaptive sampling pipeline [[25](#_bookmark30)] analyzed by Illumina® methylation 850K bead ar- ray. These samples are referred to as ”Rapid-CNS”. 3) DNA extracted from 16 glioma biopsies from patients operated at Oslo University Hospital. A separate biopsy derived from paraffin- embedded tissue was analysed with the Qiagen® *MGMT* pyrosequencing kit at the Department of Molecular Pathology, Oslo University Hospital. These samples are referred to as ”Prospective nCATs”. 4) DNA from 18 CNS tumors was extracted and sequenced in total as part of a whole genome sequecing project. These samples are referred to as ”WGSeq”. Supplementary [Table 1](#_bookmark45) provides an overview of all samples used in this study. Written, informed consent was obtained from patients at the time of surgery and reviewed by the ethical review board at the respective institutions. Samples were collected through both new and previously published studies and approved according to Regional ethical board number S-06046, 2016/1791, and 388359 [[25](#_bookmark30)]. In total, 165 samples were analyzed for *MGMT* promoter methylation status, including 103 GBM IDH-wildtype and 28 IDH-mutant glioma samples. [Figure 1b](#_bookmark1) shows distribution of sample clas- sification and predetermined methylation status. Two methods were used to enrich for the region of interest: CRISPR/Cas9-targeted sequencing of the *MGMT* promoter region [[36](#_bookmark41)] and adaptive sampling. Cas9 targeted sequencing was applied to 80 samples, 45 of which were run as single samples and 36 were run as multiplexed groups of five. 67 samples were previously

analyzed as part of an adaptive sampling pipeline. The remaining 18 samples were analyzed as part of a whole genome sequencing panel.

## Sample preparation and nanopore sequencing

Between 10 and 25 mg of fresh/frozen tissue was used to extract genomic DNA (Merck’s GenE- lute™ Mammalian Genomic DNA Miniprep kit) following the manufacturer’s protocol. Purity and concentration of DNA samples was determined using NanoDrop™ One and Qubit™ 4 Fluorom- eters (Thermo Fischer Scientific).

### nCATs

Cas9 mediated targeted sequencing was performed with the Cas9 Sequencing Kit (Oxford Nanopore Technologies) according to the manufacturers protocol (version ENR 9084 v109 revR 04Dec2018). Briefly, Cas9 ribonucleoprotein complexes (RNPs) were created by mixing equimolar concentrations (100 µM) of crispr RNA (crRNA) and trans-activating elements (tracr- RNA) to HiFi Cas9 enzyme (IDT). Dephosphorylated gDNA (2-5 µg) was cleaved and dA-tailed with Cas9 RNPs and Taq polymerase. Finally, sequencing adaptors were ligated to the cleaved fragments and the final DNA library was purified with AMPure XP beads (Beckman Coulter). Bar- codes were applied to a number of samples to allow multiplexing of five samples based on an experimental protocol from Oxford Nanopore Technologies (UNPUBLISHED Cas9 Native Bar- coding, version: cas-native-barcoding-v1-revA). Purified DNA libraries were loaded onto R9.4.1. flow cells on MinION Mk1B or Mk1C devices and sequenced for 4-24 hours. Individual flow cells were flushed and re-used up to four times for single samples and twice for multiplexed samples. A minimum pore-count of 300 was deemed sufficient for a single sample, 800 for multiplexed samples.

### Whole genome sequencing

Whole genome sequencing of CNS tumor DNA was performed with the ligation sequencing kit SQK-LSK114 and protocol (version: sqk-lsk114 GDH 9173 v114 revH 10Nov2022 promethion) from ONT. Libraries were loaded onto R10.4.1 PromethION flow-cells (one sample per flow-cell) and sequenced for 72 hours.

### RAPID-CNS

Raw fast5 sequences of all fragments mapping to the *MGMT* promoter in the Rapid-CNS [[25](#_bookmark30)] data were provided for re-analysis.

## Primers

All primers were purchased from Integrated DNA Technologies (Leuven, Belgium). Previously published primers were initially used to target the *MGMT* promoter region [[36](#_bookmark41)], termed MGMT- left-1 (ATGAGGGGCCCACTAATTGA) and MGMT-right-1 (ACCTGAGTATAGCTCCGTAC), yielding

a fragment of 2,522 bp. In order to increase cas9 efficiency and expand the size of the frag- ment, we added additional crRNA primers: MGMT-left-2 (GCCAACCACGTTAGAGACAATGG), MGMT-right-2 (GTACGGAGCTATACTCAGGT), MGMT-right3 (CTGGAATCGCATTCCAGTAGTGG)

and MGMT-right-4 (ACTTCGCAAGCATCACAGGTAGG) resulting in a fragment of 4,800 bp.

## Data analysis

Raw sequences were basecalled, methylation called and mapped (hg38, chromosome 10) using the Guppy toolbox (version 6.4.6) from ONT. Per site methylation values were extracted from modified BAM files and aggregated across forward and reverse strands using the modkit tool- box (version 0.2.2) from ONT. All statistical analyses were performed in R (version 4.2.1). The source code and data to reproduce all analyses and figures from this manuscript is available at https://github.com/SkabbiVML/MGMT\_R.

# Results

## Data acquisition

Sequence depth of the *MGMT* promoter region in the samples varied based on method, se- quencing time as well as DNA and flow-cell quality. This is reflected in the per site valid methy- lation coverage (methylated bases + canonical bases). Single sample runs produced on average more sequences in the region of interest and higher mean methylation coverage (mean = 69.4, median = 28.1) than barcoded runs (mean = 13.6, median = 10.3) and adaptive sampling (mean = 12.2, median = 9.8) ([Figure 1c](#_bookmark1)). No bias in sequencing depth was observed between methylated and unmethylated samples across Cas9 targeted or WGSeq samples, either single or multi-

plexed. However, a statistically significant difference in methylation coverage was observed between methylated (mean = 15.9, median = 16.2) and unmethylated (mean = 10.5, median = 10.6) samples analyzed by adaptive sampling (p=0.012).

## Nanopore sequencing compared to established methods

The MGMT pyro kit and the *MGMT*-STP27 classifier are common methods to infer the clini- cally relevant methylation status of *MGMT*. Both methods rely on a limited number of CpG sites. A subset of our samples (”Retrospective nCATs”, n=64) were previously analyzed using the Qiagen® *MGMT* pyrosequencing kit (MGMT pyro kit), which specifically measures CG methy- lation on four CpG sites in Chr10:129467253-129467272 (hg38) which corresponds to CpGs 76-79 of the *MGMT* CpG-island. To directly compare the results of nanopore sequencing and the MGMT pyro kit, we extracted methylation results for CpGs 76-79 with at least 3 valid methy- lation calls per site (n=62) from the nanopore data and compared them to methylation values obtained using the MGMT Pyro kit ([Figure 2](#_bookmark2)) on the same DNA sample. Pearson’s correlation coefficient between the methylation values of each overlapping CpG site between nanopore and pyrosequencing ranged from 0.89 to 0.94 (R2 = 0.79-0.89) ([Figure 2a](#_bookmark2)). Results from the MGMT pyro kit are typically returned as an average methylation percentage of all four CpGs for classification and clinical decision making. When results were averaged across all four CpG sites, the correlation increased to 0.95 (R2 = 0.91) ([Figure 2b](#_bookmark2)).

An average methylation level of *≥* 10% using the MGMT pyro kit is considered to be methylated [[17](#_bookmark22), [27](#_bookmark32)]. To compare classification results of nanopore sequencing and the MGMT pyro kit, a logistic regression model was trained using the average methylation of CpGs 76-79 based on nanopore sequencing and classification based on the MGMT pyro kit as indicator. An ROC curve of the fitted model showed an AUC of 0.992 ([Figure 2c](#_bookmark2)). The optimal methylation percentage by nanopore sequencing to separate methylated and unmethylated samples as classified by MGMT pyro kit was 22% methylated (95% confidence intervals <10% and >33% methylated). When this logistic regression model was applied to the remaining samples to predict methylation status, sensitivity and specificity was reduced with an AUC of 0.951. Two of 62 samples (3.2%) in the training set (Retrospective nCATs) and 12 of the 98 remaining samples (12.2%) did not match the known *MGMT* methylation status ([Figure 2d](#_bookmark2)).

Illumina® Human Methylation BeadChips (HM-27K, HM-450K, and HM-850K) are microarray-

based platforms used to investigate DNA methylation patterns in human samples. These plat- forms only cover a subset of the approximately 30 million CpG sites in the human genome [[18](#_bookmark23)]. To predict the clinically relevant methylation status of *MGMT*, a regression model, *MGMT STP27*, has previously been developed. This model uses the methylation status of two array probes, cg12434587 and cg12981137, as reported by Bady *et al.* [[2](#_bookmark8), [1](#_bookmark6)]. These probes corre- spond to CpG sites 31 and 84 in the *MGMT* CpG-island ([Figure 1a](#_bookmark1).

The samples from the Rapid-CNS study (n=67) were analyzed by Illumina® HM-850K EPIC array in addition to nanopore sequencing and the ground truth methylation status was derived from the *MGMT*-STP27 classifier. To compare nanopore sequencing results to the *MGMT*-STP27 classifier results, the methylation level of the two CpG sites represented in the *MGMT*-STP27 algorithm were extracted from the nanopore results and the methylation percentage values were plotted against each other ([Figure 3a](#_bookmark3)). The unmethylated samples generally show low methy- lation on both sites while methylated samples display a varied degree of methylation on both sites. A multiple logistic regression model based on the methylation percentage of CpG 31 and and CpG 84 in the Rapid-CNS data with known status as the indicator was generated. AUC of the training model was 0.972. ([Figure 3b](#_bookmark3)). The model accurately predicted the *MGMT* known methylation status of 77 of the remaining 97 samples (80%) with an AUC of 0.944.

## Clustering based on nanopore sequencing separates methylated and unmethy- lated samples

To investigate the impact of methylation at all CpG sites within the *MGMT* CpG-island, we compared the average methylation percentage of each CpG site between methylated and un- methylated samples ([Figure 4a](#_bookmark4)). These values demonstrated that the biggest differences in methylation levels occur at CpGs 7 through 14 and 72 through 91. Welch’s two sided t-tests between methylated and unmethylated samples were performed at every CpG site and the re- sults were adjusted for multiple testing (Bonferroni method). [Figure 4b](#_bookmark4) shows the adjusted p-values for every site in the *MGMT* CpG-island. Interestingly, low p-values were observed at CpG sites 4 through 14 (excluding CpG 7) which are far upstream of DMR1 and DMR2 ([Figure 1a](#_bookmark1)). Furthermore, 19 CpG sites were found to have lower p-values when comparing methylated and unmethylated samples than the CpG sites included in the MGMT pyro kit (CpGs 76-79) or the

*MGMT*-STP27 classifier (CpGs 31 and 84) [Figure 4b](#_bookmark4).

Unsupervised hierarchical clustering based on all 98 CpG sites of the CpG-island using Ward’s method revealed two main clusters that largely correspond to the previously determined clas- sification as *MGMT* methylated or unmethylated([Figure 4c](#_bookmark4)). Unmethylated samples exhibited low methylation levels throughout the CpG-island, except for the first 5 CpG sites, which were often methylated regardless of overall methylation status of the sample. In contrast, methylated samples showed a larger gradient of methylation, with higher levels of methylation towards ei- ther end of the *MGMT* CpG-island.

Clustering based on nanopore sequencing data recategorized nine samples, which have been previously classified as methylated, as otherwise unmethylated samples. In turn, there were seven previously defined unmethylated samples that were recategorized as otherwise methy- lated samples ([Figure 4c](#_bookmark4)). This pattern of separation is also evident when unsupervised clus- tering was performed on GBM samples only ([Figure 5a](#_bookmark5)).

## Survival analysis of GBM patients based on nanopore sequencing

Due to the discrepancies observed between predetermined *MGMT* methylation status and clus- tering by nanopore sequencing, we investigated whether clustering by nanopore sequencing was comparable to established methods in predicting patient survival. We performed survival analysis on 27 GBM patients under 75 years of age (11 females, average age 58.4 years and 19 males, average age 60.2 years) undergoing resection followed by radiotherapy in combination with concomitant and adjuvant temozolomide administration. Biopsies were analyzed by both MGMT pyro kit and nanopore sequencing ([Table 1](#_bookmark0)). Patients were classified as methylated or unmethylated based on the 10% cut-off value by the MGMT pyro kit and by separation into the two major clusters by hierarchical clustering of nanopore sequencing data [Figure 5a](#_bookmark5).

Kaplan-Meier survival analysis showed longer median survival of patients that were classified based on the MGMT pyro kit as methylated compared to patients classified as unmethylated ([Figure 5b](#_bookmark5), 23.8 months vs. 20.9 months). However, the difference in survival did not reach sta- tistical significance (p=0.81). When patients were classified according to clustering of nanopore sequencing data, significantly longer survival was observed in ”Cluster 2” patients compared to ”Cluster 1” patients ([Figure 5c](#_bookmark5), 24.5 months vs. 21.1 months, p=0.0039). Clusters 1 and 2 largely represent unmethylated and methylated patients based on MGMT pyro kit, respectively, with few exceptions.

# Discussion

Ever since *MGMT* promoter methylation was discovered as a prognostic marker for over-all and progression-free survival in GBM [[12](#_bookmark17), [7](#_bookmark12)], there has been an ongoing debate regarding the optimal method and optimal cut-off to determine clinically relevant methylation of the *MGMT* promoter (Supplementary [Table 2](#_bookmark46)). Methylation-specific PCR, pyrosequencing and methylation bead arrays are commonly used to determine *MGMT* methylation status, but direct comparison of the results of these methods have been discordant in up to a third of cases [[33](#_bookmark38), [11](#_bookmark16), [17](#_bookmark22)]. This is likely due to lack of consensus between CpG sites queried by different methods and different cut-offs applied. A recent meta-analysis including 32 cohorts and 3474 patients could not draw strong conclusions on the optimal CpG sites to investigate or the optimal cut-off to apply [[3](#_bookmark7)]. This underlines the need for thorough method validation by every institution on their own patient cohort. Considerable effort has been put into finding a minimal set of CpG sites within the *MGMT* CpG-island that can best predict *MGMT* expression and/or patient survival [[1](#_bookmark6), [17](#_bookmark22), [4](#_bookmark9), [29](#_bookmark34), [31](#_bookmark36), [20](#_bookmark25)]. This is partially due to the necessity to provide simplified assays that fit the short-read framework of bisulfite sequencing techniques. Most, if not all, clinically established methods of *MGMT* methylation classification, such as methylation specific PCR, quantitative methylation specific PCR, MGMT pyro kit or the *MGMT* SPT27 classifier, rely on the methylation status of very limited number of CpG sites to predict the methylation status of *MGMT*. Although these assays have been shown to largely agree on highly methylated or completely unmethylated samples, they are less reliable when it comes to moderately methylated or ’grey-zone’ samples [[34](#_bookmark39)].

Analysis of *MGMT* methylation by nanopore sequencing has several advantages over conven- tional techniques. First, nanopore sequencing can detect epigenetic modifications on native DNA, thereby circumventing the need for bisulfite treatment. This saves time and reduces the potential risk of bias introduced by bisulfite treatment and PCR that has been shown to under- represent densely hydroxymethylated (5hmC) regions [[15](#_bookmark20)]. Using native DNA without manip- ulation or amplification minimizes this bias and reduces the risk of bias between sequencing data generated by different laboratories. Secondly, the long-read nature of nanopore sequenc- ing offers a complete overview of methylation of the region of interest and can be extended in either direction to include the shores and shelves of the CpG-island. Regions outside the DMR2 are neglected by most established assays but have been shown to discriminate the methylation

status of *MGMT* in GBMs [[33](#_bookmark38)]. Third, the flexibility of nanopore sequencing makes it possible to incorporate *MGMT* methylation analysis to assays such as whole genome sequencing, exome sequencing, *in silico* enrichment (adaptive sampling) or cas9 targeted enrichment, either as sin- gle samples or multiplexed. Finally, the up-front cost of nanopore sequencing is low compared to other sequencing techniques and can be established by smaller laboratories or clinics.

In this study we analyzed 165 CNS tumor samples using targeted or whole genome nanopore se- quencing and compared the results to those acquired by pyrosequencing and methylation bead arrays. We reported 95% correlation between nanopore sequencing of the four CpG sites ana- lyzed by the MGMT-pyro kit and established an optimal cut-off for nanopore sequencing of the same CpG sites to recreate the pyrosequencing results with 97% accuracy. We also recreated sample classification via methylation bead array and the *MGMT*-STP27 classifier with nanopore sequencing data with 91% accuracy. Thus, nanopore sequencing of the *MGMT* CpG island can be used to recreate methylation status classification of either the MGMT pyro kit or methylation bead array and the *MGMT*-STP27 classifier with reasonable accuracy. In addition, nanopore sequencing allowed expansion of the area of analysis to include all 98 CpGs of the *MGMT* CpG-island as previously proposed to be critical for MGMT expression [[22](#_bookmark27)]. Unsupervised hi- erarchical clustering of samples based on nanopore methylation data of the *MGMT* CpG-island showed clear separation into groups that largely correspond to methylated and unmethylated samples. Finally, we showed that patient survival prediction based on clustering of nanopore sequencing data was comparable, if not superior, to classification via the MGMT Pyro kit. To the best of our knowledge, this is the first study to examine all 98 CpG sites within the *MGMT* CpG-island in multiple patient biopsies by nanopore sequencing.

The results presented here demonstrate that nanopore sequencing of the *MGMT* promoter re- gion can largely recreate the results of established bisulfite dependant methods while providing additional data on epigenetic regulation of *MGMT* and may provide novel criteria for patient stratification. Although the sample size is small, our results suggest that classifying patients via nanopore sequencing is as reliable as classification with methods such as the MGMT pyro kit or methylation bead arrays. Unsupervised hierarchical clustering of glioblastoma samples based on nanopore sequencing indicates the presence of one or more sub-groups within the previously defined methylated samples. These groups are defined by both extent and level of methylation. Further studies and larger patient cohorts are needed to elucidate the functional

implications of these sub-groups.

The study is not without limitations. Although 165 patients were included for the evaluation of nanopore sequencing as a method to analyse *MGMT* CpG-island methylation, only 103 samples were from diagnosed GBM patients and survival data from primary GBM patients was only avail- able for 27 patients. This limited our ability to evaluate survival beyond the major groups. Our data do not include estimation of tumor-cell content in the biopsies and do not take into ac- count the possibilities of intratumoral heterogeneity for *MGMT* promoter methylation, which has previously been shown to affect some gliomas [[35](#_bookmark40)]. It is also important to note that high-quality genomic DNA from fresh or fresh-frozen tumor tissue is crucial for MGMT methylation analysis via nanopore sequencing. While the clustering of nanopore sequencing data effectively distin- guished between methylated and unmethylated samples, notable discordances emerged when compared to results obtained through conventional methods. This discrepancy underscores the existing uncertainties inherent in the current classification of *MGMT* methylation status and highlights the need for additional investigations. The remarkable granularity of nanopore data offers a promising foundation for refining classification, especially in borderline cases. Future studies leveraging the nuanced information provided by nanopore sequencing have the poten- tial to enhance the accuracy and reliability of *MGMT* methylation status determination.

We conclude that methylation status evaluation by nanopore sequencing of the *MGMT* CpG- island is comparable to established methods while providing considerable additional infor- mation. This is true for both cas9 targeted sequencing of the *MGMT* CpG-island and in- clusion of the *MGMT* promoter region into an adaptive sequencing panel or whole genome sequencing. Distinct subgroups within methylated samples were observed via nanopore se- quencing although any difference in patient outcome between these clusters has yet to be determined.

# Acknowledgements

The authors would like to thank the patients who participated in this study and their families. We also thank Dr. Thidathip Wongsurawat for sharing her knowledge on Cas9 targeted sequencing and primer sequences. This project was funded through generous grants from The Regional Health authorities HSØ #2017073, #2021039, and #2023059.

# Tables

Table 1: Patients included in survival analysis

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Age** | **Sex** | **Resection** | **OS (months)** | **Status** | ***MGMT* status (Pyro)** | **NP cluster** |
| 60 | M | GTR | 29.26 | Dead | Methylated | 2 |
| 65 | M | STR | 29.69 | Dead | Methylated | 2 |
| 64 | M | STR | 25.48 | Dead | Methylated | 1 |
| 58 | M | STR | 21.60 | Dead | Methylated | 2 |
| 72 | F | STR | 21.21 | Dead | Methylated | 2 |
| 58 | F | STR | 13.61 | Dead | Methylated | 2 |
| 66 | M | STR | 21.96 | Dead | Methylated | 2 |
| 51 | M | GTR | 12.85 | Dead | Methylated | 2 |
| 58 | M | STR | 24.50 | Dead | Methylated | 2 |
| 57 | F | STR | 28.77 | Dead | Methylated | 2 |
| 64 | F | STR | 8.30 | Dead | Methylated | 1 |
| 52 | F | STR | 23.00 | Dead | Methylated | 2 |
| 66 | F | STR | 13.60 | Dead | Methylated | 2 |
| 51 | M | GTR | 26.00 | Dead | Methylated | 1 |
| 46 | F | GTR | 26.90 | Alive | Methylated | 2 |
| 60 | F | GTR | 21.20 | Dead | Methylated | 1 |
| 66 | M | GTR | 34.40 | Dead | Methylated | 2 |
| 39 | F | GTR | 26.30 | Alive | Methylated | 1 |
| 29 | M | GTR | 35.34 | Dead | UnMethylated | 2 |
| 62 | F | STR | 6.90 | Dead | UnMethylated | 1 |
| 58 | M | STR | 11.44 | Dead | UnMethylated | 1 |
| 66 | F | GTR | 14.99 | Dead | UnMethylated | 1 |
| 73 | M | STR | 20.91 | Dead | UnMethylated | 1 |
| 57 | M | GTR | 21.90 | Dead | UnMethylated | 1 |
| 52 | M | GTR | 26.30 | Dead | UnMethylated | 1 |
| 49 | M | GTR | 9.40 | Dead | UnMethylated | 1 |
| 55 | M | GTR | 27.70 | Alive | UnMethylated | 2 |

# Figure legends

Figure 1: (a) Schematic overview of the 98 CpG sites of the *MGMT* CpG-island with relevant functional areas including the transcription start site (TSS), minimal promoter and enhancer as defined by Harris *et al.* [[9](#_bookmark14), [10](#_bookmark15)] as well as the differentially methylated regions (DMR) one and two as described by Malley *et al.* [[21](#_bookmark26)]. The two CpG sites used by the *MGMT*-STP27 classifier [[2](#_bookmark8)] and the four CpG sites included in the Qiagen® *MGMT* pyrosequencing kit are shown below. (b) Distribution of diagnosis and known methylation status of the sample cohort. (c) Median methylation coverage of the 98 CpG sites in the *MGMT* promoter region of methylated and unmethylated samples by method of acquisition (Adaptive sampling, multiplexed nCats, single sample nCats and whole genome sequencing).

Figure 2: Comparison of nanopore sequencing and Qiagen® MGMT pyro kit of CpGs 76-79 in the *MGMT* CpG-island. Results show per-site methylation percentage of each CpG (a) or average values of 4 CpG sites analyzed by the MGMT pyro kit (b) in the ”retrospective nCATs” samples. Black vertical line marks the 10 % cut-off value between methylated and unmethylated samples as measured by the MGMT pyro kit. (c) ROC curves for a logistic regression model based on average methylation of CpGs 76-79 by nanopore sequencing (Retrospective nCATs, 60 samples) with classification by the MGMT pyro kit as operator (solid black) and prediction of MGMT status of 98 samples (dashed grey). (d) Comparison of known *MGMT* status (methylated or unmethylated, x-axis) based on the optimal average methylation threshold of CpGs 76-79 derived from the training samples (retrospective nCATs) and model predictions (other samples). The Y-axis represents average methylation percentage of CpG sites 76-79 based on nanopore sequencing. Dashed horizontal line represents the optimal threshold of 22% methylated, grey box represents 1-95% confidence interval (<10% and >33%)

Figure 3: Comparison of nanopore sequencing and the *MGMT*-STP27 classifier. (a) Methylation percentage of CpG 31 (probe ID: cg12434587) and CpG 84 (probe ID: cg12981137) in the *MGMT* promoter for 65 samples in the Rapid-CNS cohort (left) and remaining samples (right). Ellipses represent 90% confidence intervals. (b) ROC curves for a logistic regression model based on methylation of CpGs 31 and 84 by nanopore sequencing (Rapid-CNS) with classification by the *MGMT*-STP27 classifier as operator (solid black) and prediction of MGMT status of 96 remaining samples (dashed grey). (c) Separation of samples based on the linear predictors extracted from the logistic regression model.

Figure 4: (a) Dotplot showing average methylation percentage of each CpG site in the *MGMT* CpG-island. Error bars represent standard deviation. (b) Dotplot showing Bonferroni adjusted p-values of Welch’s two-sided t-test between methylated and unmethylated samples for each CpG site. Grey vertical bar shows the location of CpG sites analyzed by the MGMT pyro kit, asterixes show the location of probes included in the *MGMT*-STP27 classifier. Horizontal line depicts adjusted p-value of 0.01. (c) Unsupervised hierarchical clustering of all samples based on nanopore sequencing of 98 CpG sites of the *MGMT* promoter CpG-island (n = 165).

Figure 5: (a) Heatmap showing unsupervised clustering of all glioblastoma samples based on nanopore sequencing of the *MGMT* promoter (n = 103). Kaplan-Meier patient survival curves based on (b) MGMT pyro kit classification or (c) hierarchical clustering according to nanopore sequencing. Dotted lines represent group median survival (Pyrosequencing-methylated = 22.5 months, Pyrosequencing-unmethylated = 17.9 months, Nanopore-Cluster1 = 20.9 months, Nanopore Cluster2 = 23.0 months).

# References

1. Bady, P., Delorenzi, M., and Hegi, M. E. Sensitivity Analysis of the MGMT-STP27 Model and Impact of Genetic and Epigenetic Context to Predict the MGMT Methylation Status in Gliomas and Other Tumors. *Journal of Molecular Diagnostics 18*, 3 (2016).Bady, P., Sciuscio, D., Diserens, A. C., Bloch, J., Van Den Bent, M. J., Marosi, C., Dietrich, P. Y., Weller, M., Mariani, L., Heppner, F. L., Mcdonald, D. R., Lacombe, D., Stupp, R., Delorenzi, M., and Hegi, M. E. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP- status. *Acta neuropathologica 124*, 4 (2012), 547–560.
2. Brandner, S., McAleenan, A., Kelly, C., Spiga, F., Cheng, H. Y., Dawson, S., Schmidt, L., Faulkner, C. L., Wragg, C., Jefferies, S., Higgins, J. P., and Kurian, K. M. MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: A comprehensive meta-analysis based on a Cochrane Systematic Review. *Neuro-Oncology 23*, 9 (9 2021), 1457–1469.
3. Brigliadori, G., Foca, F., Dall’Agata, M., Rengucci, C., Melegari, E., Cerasoli, S., Amadori, D., Calistri, D., and Faedi, M. Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. *Journal of Neuro-Oncology 128*, 2 (2016).
4. Choi, H. J., Choi, S. H., You, S. H., Yoo, R. E., Kang, K. M., Yun, T. J., Kim, J. H., Sohn, C. H.,

Park, C. K., and Park, S. H. MGMT promoter methylation status in initial and recurrent glioblastoma: Correlation study with DWI and DSC PWI features. *American Journal of* *Neuroradiology 42*, 5 (2021).

1. Christmann, M., Verbeek, B., Roos, W. P., and Kaina, B. O6-Methylguanine-DNA methyl- transferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer* *1816*, 2 (12 2011), 179–190.
2. Dovek, L., Nguyen, N. T., Ozer, B. H., Li, N., Elashoff, R. M., Green, R. M., Liau, L., Leia Nghiem- phu, P., Cloughesy, T. F., and Lai, A. Correlation of commercially available quantita- tive MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival. *Neuro-Oncology Practice 6*, 3 (2019).
3. Gilpatrick, T., Lee, I., Graham, J. E., Raimondeau, E., Bowen, R., Heron, A., Downs, B., Suku- mar, S., Sedlazeck, F. J., and Timp, W. Targeted nanopore sequencing with Cas9-guided adapter ligation. *Nature biotechnology 38*, 4 (4 2020), 433–438.
4. Harris, L. C., Potter, P. M., Tano, K., Shiota, S., Mitra, S., and Brent, T. P. Characterization of the promoter region of the human O6-methylguanine-DNA methyltransferase gene. *Nucleic* *Acids Research 19*, 22 (1991).
5. Harris, L. C., Remack, J. S., and Brent, T. P. Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine DNA methyltransferease gene. *Nucleic Acids Research 22*, 22 (1994).
6. Håvik, A. B., Brandal, P., Honne, H., Dahlback, H. S. S., Scheie, D., Hektoen, M., Meling,

T. R., Helseth, E., Heim, S., Lothe, R. A., and Lind, G. E. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. *Jour-* *nal of Translational Medicine 10*, 1 (3 2012).

1. Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., Bromberg, J. E., Hau, P., Mirimanoff, R. O., Cairn- cross, J. G., Janzer, R. C., and Stupp, R. MGMT Gene Silencing and Benefit from Temo- zolomide in Glioblastoma . *New England Journal of Medicine 352*, 10 (2005).
2. Hegi, M. E., Genbrugge, E., Gorlia, T., Stupp, R., Gilbert, M. R., Chinot, O. L., Burt Nabors, L., Jones, G., Van Criekinge, W., Straub, J., and Weller, M. MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: A pooled analysis of four clinical trials. *Clinical Cancer Research 25*, 6 (2019), 1809–1816.
3. Hegi, M. E., and Ichimura, K. MGMT testing always worth an emotion. *Neuro-Oncology 23*, 9 (9 2021), 1417.
4. Huang, Y., Pastor, W. A., Shen, Y., Tahiliani, M., Liu, D. R., and Rao, A. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. *PLoS ONE 5*, 1 (1 2010).
5. Jain, M., Olsen, H. E., Paten, B., and Akeson, M. The Oxford Nanopore MinION: Delivery of nanopore sequencing to the genomics community. *Genome Biology 17*, 1 (2016).
6. Johannessen, L. E., Brandal, P., Myklebust, T. ., Heim, S., Micci, F., and Panagopoulos,
   1. MGMT gene promoter methylation status – Assessment of two pyrosequencing kits and three methylation-specific PCR methods for their predictive capacity in glioblastomas. *Cancer Genomics and Proteomics 15*, 6 (11 2018), 437–446.
7. Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar,

K., Doyle, M., Fitzhugh, W., Funke, R., Gage, D., Harris, K., Heaford, A., Howland, J., Kann, L., Lehoczky, J., Levine, R., McEwan, P., McKernan, K., Meldrim, J., Mesirov, J. P., Miranda, C., Morris, W., Naylor, J., Raymond, C., Rosetti, M., Santos, R., Sheridan, A., Sougnez, C., Stange- Thomann, N., Stojanovic, N., Subramanian, A., Wyman, D., Rogers, J., Sulston, J., Ainscough, R., Beck, S., Bentley, D., Burton, J., Clee, C., Carter, N., Coulson, A., Deadman, R., Deloukas, P., Dunham, A., Dunham, I., Durbin, R., French, L., Grafham, D., Gregory, S., Hubbard, T., Humphray, S., Hunt, A., Jones, M., Lloyd, C., McMurray, A., Matthews, L., Mercer, S., Milne, S., Mullikin, J. C., Mungall, A., Plumb, R., Ross, M., Shownkeen, R., Sims, S., Waterston,

R. H., Wilson, R. K., Hillier, L. W., McPherson, J. D., Marra, M. A., Mardis, E. R., Fulton, L. A.,

Chinwalla, A. T., Pepin, K. H., Gish, W. R., Chissoe, S. L., Wendl, M. C., Delehaunty, K. D.,

Miner, T. L., Delehaunty, A., Kramer, J. B., Cook, L. L., Fulton, R. S., Johnson, D. L., Minx, P. J., Clifton, S. W., Hawkins, T., Branscomb, E., Predki, P., Richardson, P., Wenning, S., Slezak, T., Doggett, N., Cheng, J. F., Olsen, A., Lucas, S., Elkin, C., Uberbacher, E., Frazier, M., Gibbs,

R. A., Muzny, D. M., Scherer, S. E., Bouck, J. B., Sodergren, E. J., Worley, K. C., Rives, C. M., Gorrell, J. H., Metzker, M. L., Naylor, S. L., Kucherlapati, R. S., Nelson, D. L., Weinstock, G. M., Sakaki, Y., Fujiyama, A., Hattori, M., Yada, T., Toyoda, A., Itoh, T., Kawagoe, C., Watanabe, H., Totoki, Y., Taylor, T., Weissenbach, J., Heilig, R., Saurin, W., Artiguenave, F., Brottier, P., Bruls, T., Pelletier, E., Robert, C., Wincker, P., Rosenthal, A., Platzer, M., Nyakatura, G., Taudien, S., Rump, A., Smith, D. R., Doucette-Stamm, L., Rubenfield, M., Weinstock, K., Hong, M. L., Dubois, J., Yang, H., Yu, J., Wang, J., Huang, G., Gu, J., Hood, L., Rowen, L., Madan, A., Qin,

S., Davis, R. W., Federspiel, N. A., Abola, A. P., Proctor, M. J., Roe, B. A., Chen, F., Pan, H., Ramser, J., Lehrach, H., Reinhardt, R., McCombie, W. R., De La Bastide, M., Dedhia, N., Blöcker, H., Hornischer, K., Nordsiek, G., Agarwala, R., Aravind, L., Bailey, J. A., Bateman, A., Batzoglou, S., Birney, E., Bork, P., Brown, D. G., Burge, C. B., Cerutti, L., Chen, H. C., Church,

D., Clamp, M., Copley, R. R., Doerks, T., Eddy, S. R., Eichler, E. E., Furey, T. S., Galagan, J., Gilbert, J. G., Harmon, C., Hayashizaki, Y., Haussler, D., Hermjakob, H., Hokamp, K., Jang, W., Johnson, L. S., Jones, T. A., Kasif, S., Kaspryzk, A., Kennedy, S., Kent, W. J., Kitts, P., Koonin,

E. V., Korf, I., Kulp, D., Lancet, D., Lowe, T. M., McLysaght, A., Mikkelsen, T., Moran, J. V., Mulder, N., Pollara, V. J., Ponting, C. P., Schuler, G., Schultz, J., Slater, G., Smit, A. F., Stupka, E., Szustakowki, J., Thierry-Mieg, D., Thierry-Mieg, J., Wagner, L., Wallis, J., Wheeler, R., Williams, A., Wolf, Y. I., Wolfe, K. H., Yang, S. P., Yeh, R. F., Collins, F., Guyer, M. S., Peterson,

J., Felsenfeld, A., Wetterstrand, K. A., Myers, R. M., Schmutz, J., Dickson, M., Grimwood, J., Cox, D. R., Olson, M. V., Kaul, R., Raymond, C., Shimizu, N., Kawasaki, K., Minoshima, S., Evans, G. A., Athanasiou, M., Schultz, R., Patrinos, A., and Morgan, M. J. Initial sequencing and analysis of the human genome. *Nature 409*, 6822 (2001).

1. Laver, T., Harrison, J., O’Neill, P. A., Moore, K., Farbos, A., Paszkiewicz, K., and Studholme,

D. J. Assessing the performance of the Oxford Nanopore Technologies MinION. *Biomolec-* *ular Detection and Quantification 3* (2015).

1. Leske, H., Camenisch Gross, U., Hofer, S., Neidert, M. C., Leske, S., Weller, M., Lehnick, D., and Rushing, E. J. MGMT methylation pattern of long-term and short-term survivors of glioblastoma reveals CpGs of the enhancer region to be of high prognostic value. *Acta* *neuropathologica communications 11*, 1 (12 2023).
2. Malley, D. S., Hamoudi, R. A., Kocialkowski, S., Pearson, D. M., Collins, V. P., and Ichimura,

K. A distinct region of the MGMT CpG island critical for transcriptional regulation is pref- erentially methylated in glioblastoma cells and xenografts. *Acta Neuropathologica 121*, 5 (2011).

1. Nakagawachi, T., Soejima, H., Urano, T., Zhao, W., Higashimoto, K., Satoh, Y., Matsukura, S., Kudo, S., Kitajima, Y., Harada, H., Furukawa, K., Matsuzaki, H., Emi, M., Nakabeppu, Y., Miyazaki, K., Sekiguchi, M., and Mukai, T. Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene ex- pression in human cancer. *Oncogene 22*, 55 (2003).
2. Nguyen, N., Redfield, J., Ballo, M., Michael, M., Sorenson, J., Dibaba, D., Wan, J., Ramos,

G. D., and Pandey, M. Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma. *CNS Oncology 10*, 3 (2021).

1. Ostrom, Q. T., Patil, N., Cioffi, G., Waite, K., Kruchko, C., and Barnholtz-Sloan, J. S. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. *Neuro-Oncology 22*, Supplement\_1 (10 2020), IV1–IV96.
2. Patel, A., Dogan, H., Payne, A., Krause, E., Sievers, P., Schoebe, N., Schrimpf, D., Blume, C., Stichel, D., Holmes, N., Euskirchen, P., Hench, J., Frank, S., Rosenstiel-Goidts, V., Ratliff, M., Etminan, N., Unterberg, A., Dieterich, C., Herold-Mende, C., Pfister, S. M., Wick, W., Loose, M., von Deimling, A., Sill, M., Jones, D. T., Schlesner, M., and Sahm, F. Rapid-CNS2: rapid

comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study.

*Acta neuropathologica 143*, 5 (5 2022), 609–612.

1. Payne, A., Holmes, N., Clarke, T., Munro, R., Debebe, B., and Loose, M. Nanopore adaptive sequencing for mixed samples, whole exome capture and targeted panels. *bioRxiv* (2020).
2. Quillien, V., Lavenu, A., Ducray, F., Meyronet, D., Chinot, O., Fina, F., Sanson, M., Carpen- tier, C., Karayan-Tapon, L., Rivet, P., Entz-Werle, N., Legrain, M., Zalcman, E. L., Levallet, G., Escande, F., Ramirez, C., Chiforeanu, D., Vauleon, E., and Figarella-Branger, D. Clinical val- idation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients. *Cancer Biomarkers 20*, 4 (2017).
3. Quillien, V., Lavenu, A., Karayan-Tapon, L., Carpentier, C., Labussiã̈ re, M., Lesimple, T., Chinot, O., Wager, M., Honnorat, J., Saikali, S., Fina, F., Sanson, M., and Figarella-Branger, D. Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immuno- histochemistry) to analyze O6-methylguanine-DNA- methyltranferase in a series of 100 glioblastoma patients. *Cancer 118*, 17 (2012).
4. Radke, J., Koch, A., Pritsch, F., Schumann, E., Misch, M., Hempt, C., Lenz, K., Löbel, F., Paschereit, F., Heppner, F. L., Vajkoczy, P., Koll, R., and Onken, J. Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients. *Acta neuropathologica* *communications 7*, 1 (2019).
5. Sahm, F., Brandner, S., Bertero, L., Capper, D., French, P. J., Figarella-Branger, D., Gian- gaspero, F., Haberler, C., Hegi, M. E., Kristensen, B. W., Kurian, K. M., Preusser, M., Tops, B.

B. J., van den Bent, M., Wick, W., Reifenberger, G., and Wesseling, P. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline. *Neuro-oncology* (6 2023).

1. Siller, S., Lauseker, M., Karschnia, P., Niyazi, M., Eigenbrod, S., Giese, A., and Tonn, J. C. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. *Acta neuropathologica communica-* *tions 9*, 1 (3 2021), 35.
2. Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., Di Meco, F., Lieberman, F., Zhu, J. J., Stragliotto, G., Tran, D. D.,

Brem, S., Hottinger, A. F., Kirson, E. D., Lavy-Shahaf, G., Weinberg, U., Kim, C. Y., Paek,

S. H., Nicholas, G., Burna, J., Hirte, H., Weller, M., Palti, Y., Hegi, M. E., and Ram, Z. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma a randomized clinical trial. *JAMA - Journal* *of the American Medical Association 318*, 23 (2017).

1. Tierling, S., Jürgens-Wemheuer, W. M., Leismann, A., Becker-Kettern, J., Scherer, M., Wrede, A., Breuskin, D., Urbschat, S., Sippl, C., Oertel, J., Schulz-Schaeffer, W. J., and Walter, J. Bisul- fite profiling of the MGMT promoter and comparison with routine testing in glioblastoma diagnostics. *Clinical Epigenetics 14*, 1 (2022).
2. Torre, M., Wen, P. Y., and Iorgulescu, J. B. The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients . *Neuro-Oncology Practice* (2022).
3. Wenger, A., Vega, S. F., Kling, T., Bontell, T. O., Jakola, A. S., and Carén, H. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. *Neuro-Oncology 21*, 5 (5 2019), 616.
4. Wongsurawat, T., Jenjaroenpun, P., De Loose, A., Alkam, D., Ussery, D. W., Nookaew, I., Leung, Y. K., Ho, S. M., Day, J. D., and Rodriguez, A. A novel Cas9-targeted long-read assay for simultaneous detection of IDH1/2 mutations and clinically relevant MGMT methylation in fresh biopsies of diffuse glioma. *Acta Neuropathologica Communications 8*, 1 (6 2020),

1–13.

1. Xie, H., Tubbs, R., and Yang, B. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. *International Journal of Clinical and Experimental Pathology 8*, 2 (2015).
2. Yuan, G., Niu, L., Zhang, Y., Wang, X., Ma, K., Yin, H., Dai, J., Zhou, W., and Pan, Y. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. *Journal of Neuro-Oncology 133*, 1 (2017).
3. Zhang, J., F.G. Stevens, M., and D. Bradshaw, T. Temozolomide: Mechanisms of Action, Repair and Resistance. *Current Molecular Pharmacology 5*, 1 (2011).

# Supplementary material

Table 1: Summary of samples included in this study

2

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Prospective nCats | Retrospective nCats | Rapid-CNS | WGSeq | Total |
| Glioblastoma, IDHwt | 13 | 28 | 49 | 13 | **103** |
| Astrocytoma, IDHmut | 3 | 1 | 3 | 2 | **9** |
| Astrocytoma HG, IDHmut | 0 | 4 | 4 | 1 | **9** |
| Oligodendroglioma, IDHmut | 0 | 2 | 6 | 2 | **10** |
| Meningioma | 0 | 12 | 0 | 0 | **12** |
| Atypical teratoid/rhabdoid tumor | 0 | 0 | 1 | 0 | **1** |
| Ganglioglioma | 0 | 1 | 0 | 0 | **1** |
| Hemangiopericytoma | 0 | 1 | 0 | 0 | **1** |
| Pilocytic astrocytoma | 0 | 0 | 4 | 0 | **4** |
| Medulloblastoma | 0 | 1 | 0 | 0 | **1** |
| Metastasis | 0 | 7 | 0 | 0 | **7** |
| Lymphoma | 0 | 2 | 0 | 0 | **2** |
| Pleomorphic xanthoastrocytoma | 0 | 2 | 0 | 0 | **2** |
| Unknown | 0 | 3 | 0 | 0 | **3** |
| **Total** | **16** | **64** | **67** | **18** | **165** |

Table 2: Summary of reported optimal cut-offs for determining methylated versus unmethylated samples

3

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Author | Year | Method | Patients | CpGs | Optimal cut-off | Comment | Reference |
| Hegi | 2019 | qMSP | 4041 |  | >1.27 | ”Grey-zone” patients benefit from TMZ | [[13](#_bookmark18)] |
| Johannessen | 2018 | qMSP, PSQ | 48 |  | 7 % | PSQ gives better results than other methods | [[17](#_bookmark22)] |
| Nguyen | 2021 | PSQ | 109 |  | 21 % | Higher methylation corrilates with longer OS | [[23](#_bookmark28)] |
| Quillien | 2012 | MSP, PSQ, MS-HRM | 100 | 5 | 8 % | PSQ performs best | [[28](#_bookmark33)] |
| Xie | 2015 | PSQ | 43 |  | 10 % | Not testing cut-off | [[37](#_bookmark42)] |
| Yuan | 2017 | PSQ | 84 | 4 | 12.50 % | Higher methylation corrilates with longer OS | [[38](#_bookmark43)] |
| Brigliadori | 2016 | PSQ | 105 | 10 | 30 % | ”Grey-zone” patients do not benefit from TMZ | [[4](#_bookmark9)] |
| Radke | 2019 | PSQ, sqMSP | 111 |  | 10 % | Best results when PSQ and MSP were combined | [[29](#_bookmark34)] |
|  |  |  |  |  |  | *MGMT* promoter methylation has predictive |  |
| Chai | 2021 | PSQ | 173 | 4 | 10 % [[5](#_bookmark10)]  value in IDH-mutant glioblastoma | | |
| Dovek | 2019 | qMSP | 165 |  | ”Grey-zone” patients benefit from TMZ,  >1 [[7](#_bookmark12)]  higher methylation does not correlate with longer OS | | |
| Siller | 2021 | MSP, Sseq | 215 | 25 | Linear correlation between number of  [[31](#_bookmark36)] | | |
|  |  |  |  |  |  | methylated CpG sites and OS |  |